142808-44-4Relevant academic research and scientific papers
Biological and physicochemical characterization of siRNAs modified with 2',2'-difluoro-2'-deoxycytidine (gemcitabine)
Sierant, Malgorzata,Sobczak, Milena,Janicka, Magdalena,Paduszynska, Alina,Piotrzkowska, Danuta
, p. 918 - 924 (2010)
The use of synthetic short interfering RNAs (siRNAs) is currently a method of choice to manipulate gene expression in mammalian cells. Efforts aimed at improving siRNA biological activity, including increased silencing properties, higher substrate specifi
Aptamers Entirely Built from Therapeutic Nucleoside Analogues for Targeted Cancer Therapy
Ma, Yuan,Yang, Jiapei,Zhang, Chuan,Zhu, Lijuan,Zhu, Xinyuan
, p. 1493 - 1497 (2022/02/10)
Owing to the specific and high binding affinity of aptamers to their targets, aptamer-drug conjugates (ApDCs) have emerged as a promising drug delivery system for targeted cancer therapy. However, in a conventional ApDC, the aptamer segment usually just s
Targeting nano carrier bearing nucleoside anti-tumor drugs and preparation method and application thereof
-
Paragraph 0080; 0087-0088, (2019/02/04)
The invention provides a targeting nano carrier bearing nucleoside anti-tumor drugs and preparation method and application thereof. The targeting nano carrier comprises DNA tetrahedron, Affibody molecule and nucleoside anti-tumor drugs. The preparation me
COMPOSITION CONTAINING MODIFIED DERIVATIVES OF A CYTIDINE ANTIMETABOLITE FOR THE TREATMENT OF SUSCEPTIBLE DISEASE
-
Page/Page column 12, (2015/02/02)
The present invention relates to homo-oligomeric derivatives of a cytidine antimetabolite and its use for the treatment of susceptible diseases. The cytidine antimetabolite is preferably a compound made of 2-20 units of dFdC linked with 5' - 3' phosphate
Novel oligonucleotides and related compounds
-
Page/Page column 16, (2008/06/13)
The present invention relates generally to oligonucleotides and more specifically to oligonucleotides which have a sequence including at least two CDG dinucleotides and a prodrug of an antimetabolite. The prodrug can be part of a CpG dinucleotide or may be attached elsewhere on the oligonucleotide.
